➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Baxter
AstraZeneca
Express Scripts
Johnson and Johnson

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for ETX2514


Email this page to a colleague

« Back to Dashboard

What is the drug development status for ETX2514?

ETX2514 is an investigational drug.

There have been 7 clinical trials for ETX2514. The most recent clinical trial was a Phase 2 trial, which was initiated on March 29th 2019.

The most common disease conditions in clinical trials are Infection, Communicable Diseases, and Pneumonia, Bacterial. The leading clinical trial sponsors are Entasis Therapeutics, Clinartis, and [disabled in preview].

There are two US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for ETX2514
TitleSponsorPhase
Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male SubjectsEntasis TherapeuticsPhase 1
Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female VolunteersEntasis TherapeuticsPhase 1
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus ComplexEntasis TherapeuticsPhase 3

See all ETX2514 clinical trials

Clinical Trial Summary for ETX2514

Top disease conditions for ETX2514
Top clinical trial sponsors for ETX2514

See all ETX2514 clinical trials

US Patents for ETX2514

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ETX2514   Try Before You Buy Beta-lactamase inhibitor compounds Entasis Therapeutics Limited (London, GB)   Try Before You Buy
ETX2514   Try Before You Buy .beta.-lactamase inhibitor compounds Entasis Therapeutics Limited (London, GB)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ETX2514

Drugname Country Document Number Estimated Expiration Related US Patent
ETX2514 Argentina AR090539 2032-04-02   Try Before You Buy
ETX2514 Australia AU2013245399 2032-04-02   Try Before You Buy
ETX2514 Canada CA2866467 2032-04-02   Try Before You Buy
ETX2514 Chile CL2014002589 2032-04-02   Try Before You Buy
ETX2514 China CN104364254 2032-04-02   Try Before You Buy
ETX2514 Colombia CO7071137 2032-04-02   Try Before You Buy
ETX2514 Costa Rica CR20140428 2032-04-02   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Baxter
Merck
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.